Technology area: Biotechnology & Pharmaceuticals
28 pending office actions • 17 clients • 26 examiners • 23 art units • 0 of 28 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
K&L Gates LLP-Boston has 28 pending office actions in Biotechnology & Pharmaceuticals and 34332 career applications. Its resolved allowance rate is 84.49%, and the average office actions per allowance is 3.82. The profile combines an active Boston workload with broad historical prosecution data.
The pending matters require current docket attention, while the allowance rate and office-action average describe resolved activity. The average indicates that allowance has involved repeated examination interactions, but neither historical measure predicts a particular outcome. Practitioners should tailor strategy to the biological or pharmaceutical claim limitations, cited art, and disclosure available in each application.
Based on the USPTO statutory response window for each pending office action. 14 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 14 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 2 (7%) |
| §101 + other | 3 (11%) |
| §103 only | 3 (11%) |
| §112 only | 2 (7%) |
| Double-patenting + other | 6 (21%) |
| Multi-statute (no §101) | 12 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| XU, MICHAEL | 2 | 75.8% | +27.6% |
| HUDSON, AMY ROSE | 2 | 74.8% | +11.7% |
| KAMM, JUDITH MARIE | 1 | 42.9% | +57.1% |
| PHAM, KATHERINE-PH MINH | 1 | 59.8% | +49.7% |
| STEPHENS, AMELIA CAROLE | 1 | 75.0% | +50.0% |
| NORRIS, CLAIRE A | 1 | 66.0% | +27.9% |
| SVEIVEN, MICHAEL CAMERON | 1 | 36.0% | +49.2% |
| MAHLUM, JONATHAN DAVIS | 1 | 50.0% | +23.3% |
| PIHONAK, SARAH | 1 | 61.4% | +42.4% |
| SHIAO, YIH-HORNG | 1 | 72.6% | +75.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17730900 | Automated Healthcare Provider Quality Reporting System (PQRS) | HEIN, DEVIN C | 99d overdue |
| 18643059 | MAGNETIC FILTER APPARATUS AND METHOD | NORRIS, CLAIRE A | 60d overdue |
| 16825087 | Systems and Methods of Generating Patient Notes with Inherited Preferences | WINSTON III, EDWARD B | 60d overdue |
| 17364497 | METHOD AND SYSTEM OF GUIDING A USER ON A GRAPHICAL INTERFACE WITH COMPUTER VISION | BROUGHTON, KATHLEEN M | 15d overdue |
| 17927497 | MEMBRANE EMULSIFICATION APPARATUS WITH REFINER AND METHOD OF PREPARING A REFINED EMULSION | BASS, DIRK R | 12d |
| 18025307 | SENOLYTIC COMPOUNDS AND COMPOSITIONS | ROBINSON, MIKHAIL O'DONNEL | 14d |
| 18016143 | METHOD OF PREPARING LIPID VESICLES | SHOMER, ISAAC | 20d |
| 18282082 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | LEE, CHIHYI NMN | 36d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18643059 | MAGNETIC FILTER APPARATUS AND METHOD | NORRIS, CLAIRE A | 60d overdue |
| 18998271 | CONTINUOUS PROCESS | KAMM, JUDITH MARIE | — |
| 18984246 | ASPIRATORS, COMPONENTS THEREOF, AND ASSEMBLY AND FIT THEREOF | PHAM, KATHERINE-PH MINH | — |
| 18721114 | TIGIT ANTIBODIES AND USES THEREOF | STEPHENS, AMELIA CAROLE | — |
| 18699403 | METHOD FOR DETECTING PROTEIN HAVING CHANGES IN ENERGY STATE, OR AFFINITY OF LIGAND TO PROTEIN | SVEIVEN, MICHAEL CAMERON | — |
| 18627032 | DRUG COMBINATION OF FAK INHIBITOR AND IMMUNOGENIC CELL DEATH INDUCER AND USE THEREOF | MAHLUM, JONATHAN DAVIS | — |
| 18690561 | PHARMACEUTICAL PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF | PIHONAK, SARAH | — |
| 18434386 | IONIZABLE LIPID COMPOUNDS | SHIAO, YIH-HORNG | — |
| Art Unit | Apps |
|---|---|
| 1636 | 3 |
| 1779 | 2 |
| 1627 | 2 |
| 2113 | 2 |
| 1611 | 1 |
| 3781 | 1 |
| 1645 | 1 |
| 1678 | 1 |
| 1625 | 1 |
| 1691 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18998271 | CONTINUOUS PROCESS | Micropore Technologies Limited | KAMM, JUDITH MARIE | 1611 | §102§103§112DP | Non-Final OA | — | Pending | Jan 24, 2025 |
| 18984246 | ASPIRATORS, COMPONENTS THEREOF, AND ASSEMBLY AND FIT THEREOF | Surgimark, Inc. | PHAM, KATHERINE-PH MINH | 3781 | §103§112Other | Non-Final OA | — | Pending | Dec 17, 2024 |
| 18721114 | TIGIT ANTIBODIES AND USES THEREOF | Shanghai Nigene Biological Science And Technology Co., Ltd. | STEPHENS, AMELIA CAROLE | 1645 | §112 | Non-Final OA | — | Pending | Jun 17, 2024 |
| 18643059 | MAGNETIC FILTER APPARATUS AND METHOD | Medisieve Ltd. | NORRIS, CLAIRE A | 1779 | §102§103 | Non-Final OA | 60d overdue | Pending | Apr 23, 2024 |
| 18699403 | METHOD FOR DETECTING PROTEIN HAVING CHANGES IN ENERGY STATE, OR AFFINITY OF LIGAND TO PROTEIN | Dalian Institute Of Chemical Physics, Chinese Academy Of Sciences | SVEIVEN, MICHAEL CAMERON | 1678 | §101§102§112 | Non-Final OA | — | Pending | Apr 08, 2024 |
| 18627032 | DRUG COMBINATION OF FAK INHIBITOR AND IMMUNOGENIC CELL DEATH INDUCER AND USE THEREOF | Inxmed (Nanjing) Co., Ltd. | MAHLUM, JONATHAN DAVIS | 1625 | §102§112DP | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18690561 | PHARMACEUTICAL PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF | Coherent Biopharma (Suzhou) Limited | PIHONAK, SARAH | 1627 | §103§112DP | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18434386 | IONIZABLE LIPID COMPOUNDS | Metis Techbio Co., Ltd. | SHIAO, YIH-HORNG | 1691 | §102§103§112DP | Non-Final OA | — | Pending | Feb 06, 2024 |
| 18292582 | METHODS OF TREATING CANCER | Foghorn Therapeutics Inc. | INAM, SAHAR | 1622 | §102§103 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18399497 | SOFTWARE BASED VALIDATION OF MEMORY FOR FAULT TOLERANT SYSTEMS | Stratus Technologies Ireland Ltd. | XU, MICHAEL | 2113 | §103§112 | Non-Final OA | — | Pending | Dec 28, 2023 |
| 18282082 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED | LEE, CHIHYI NMN | 1628 | §103§112 | Final Rejection | 36d | Pending | Sep 14, 2023 |
| 18037505 | ERYTHROPOIETIN VARIANTS AND USES THEREOF | Chulabhorn Foundation | KOMATSU, LI N | 1658 | §102§103§112 | Non-Final OA | 56d | Pending | May 17, 2023 |
| 18248974 | RNA COMPOSITIONS AND METHODS FOR INHIBITING LIPOPROTEIN(A) | Sanofi | ARIETI, RUTH SOPHIA | 1635 | §103DP | Final Rejection | 3d overdue | Pending | Apr 13, 2023 |
| 18248982 | NOVEL RNA COMPOSITIONS AND METHODS FOR INHIBITING ANGPTL3 | Sanofi | HUDSON, AMY ROSE | 1636 | §102§103§112 | Final Rejection | — | Pending | Apr 13, 2023 |
| 18248988 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | Sanofi | VANHORN, ABIGAIL LOUISE | 1636 | §103§112DP | Final Rejection | 20d | Pending | Apr 13, 2023 |
| 18025307 | SENOLYTIC COMPOUNDS AND COMPOSITIONS | Nuchido Limited | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103§112 | Final Rejection | 14d | Pending | Mar 08, 2023 |
| 18106550 | HIGH RELIABILITY FAULT TOLERANT COMPUTER ARCHITECTURE | Stratus Technologies Ireland Ltd. | XU, MICHAEL | 2113 | §103 | Non-Final OA | — | Pending | Feb 07, 2023 |
| 18018078 | METHODS OF PREPARING SOLID PARTICULATE MATERIALS | Micropore Technologies Limited | HUANG, RYAN | 1777 | §103 | Final Rejection | 107d overdue | Pending | Jan 26, 2023 |
| 18016143 | METHOD OF PREPARING LIPID VESICLES | Micropore Technologies Limited | SHOMER, ISAAC | 1612 | §103§112 | Non-Final OA | 20d | Pending | Jan 13, 2023 |
| 17927497 | MEMBRANE EMULSIFICATION APPARATUS WITH REFINER AND METHOD OF PREPARING A REFINED EMULSION | Micropore Technologies Limited | BASS, DIRK R | 1779 | §102§103 | Non-Final OA | 12d | Pending | Nov 23, 2022 |
| 17730900 | Automated Healthcare Provider Quality Reporting System (PQRS) | Modernizing Medicine, Inc. | HEIN, DEVIN C | 3686 | §101§103 | Non-Final OA | 99d overdue | Pending | Apr 27, 2022 |
| 17638339 | COMPOSITIONS AND METHODS FOR INHIBITING PCSK9 | Sanofi | HUDSON, AMY ROSE | 1636 | §102§103§112 | Non-Final OA | — | Pending | Feb 25, 2022 |
| 17364497 | METHOD AND SYSTEM OF GUIDING A USER ON A GRAPHICAL INTERFACE WITH COMPUTER VISION | Edcast Inc. | BROUGHTON, KATHLEEN M | 2661 | §102§103§112 | Non-Final OA | 15d overdue | Pending | Jun 30, 2021 |
| 16980207 | METHOD OF TREATMENT | Nuchido Limited | OLSON, ANDREA STEFFEL | 1693 | §103 | Final Rejection | 73d overdue | Pending | Sep 11, 2020 |
| 16825087 | Systems and Methods of Generating Patient Notes with Inherited Preferences | Modernizing Medicine, Inc. | WINSTON III, EDWARD B | 3683 | §101 | Non-Final OA | 60d overdue | Pending | Mar 20, 2020 |
| 16631861 | METHODS AND COMPOSITIONS FOR TREATING ADDICTIONS | BAR ILAN UNIVERSITY | VIVLEMORE, TRACY ANN | 1638 | §112 | Final Rejection | 3d overdue | Pending | Jan 17, 2020 |
| 16412389 | SYSTEM AND METHOD FOR SHOWING, TESTING AND CERTIFYING USERS IN-APP ON CLOUD APPLICATION WORKFLOWS | Edcast Inc. | PRATT, EHRIN LARMONT | 3629 | §101§103 | Non-Final OA | — | Pending | May 14, 2019 |
| 15992148 | METHODS AND SYSTEMS FOR ANIMATED WALKTHROUGHS IN AN ONLINE EDUCATIONAL PLATFORM | Edcast Inc. | GRANT, MICHAEL CHRISTOPHER | 3715 | §101 | Final Rejection | — | Pending | May 29, 2018 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial84.5% of resolved applications prosecuted by K&L Gates Llp-Boston were allowed, across 34,332 applications in USPTO records.
3.82 office actions per allowed application on average.
28 pending office actions as of October 2026, for 17 clients, before 26 examiners in 23 art units.
